New York Life Investment Management LLC Has $1.43 Million Position in DaVita Inc. (NYSE:DVA)

New York Life Investment Management LLC boosted its position in DaVita Inc. (NYSE:DVA) by 2.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 13,629 shares of the company’s stock after purchasing an additional 339 shares during the quarter. New York Life Investment Management LLC’s holdings in DaVita were worth $1,428,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in DaVita by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 6,175,029 shares of the company’s stock worth $583,725,000 after purchasing an additional 65,526 shares in the last quarter. Invesco Ltd. increased its holdings in DaVita by 21.3% in the 3rd quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock worth $157,606,000 after purchasing an additional 292,767 shares in the last quarter. Deutsche Bank AG increased its holdings in DaVita by 421.8% in the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock worth $103,518,000 after purchasing an additional 885,195 shares in the last quarter. Lazard Asset Management LLC grew its position in shares of DaVita by 8.7% in the 3rd quarter. Lazard Asset Management LLC now owns 845,416 shares of the company’s stock valued at $79,916,000 after buying an additional 67,970 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of DaVita by 15.7% in the 3rd quarter. Northern Trust Corp now owns 834,608 shares of the company’s stock valued at $78,895,000 after buying an additional 113,508 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Truist Financial upped their price target on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research report on Tuesday, February 20th. UBS Group upped their price target on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Barclays upped their price target on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research report on Monday. Finally, StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a research report on Monday. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Moderate Buy” and a consensus price target of $121.33.

Insiders Place Their Bets

In other DaVita news, insider James O. Hearty sold 26,164 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the transaction, the insider now owns 20,264 shares in the company, valued at $2,424,384.96. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other DaVita news, insider Kathleen Alyce Waters sold 11,285 shares of the stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $120.73, for a total value of $1,362,438.05. Following the transaction, the insider now owns 81,297 shares in the company, valued at $9,814,986.81. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider James O. Hearty sold 26,164 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 134,540 shares of company stock worth $16,551,071. Corporate insiders own 1.40% of the company’s stock.

DaVita Stock Up 0.7 %

Shares of DaVita stock opened at $137.79 on Wednesday. DaVita Inc. has a one year low of $71.51 and a one year high of $145.04. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. The stock’s 50-day moving average is $134.15 and its 200 day moving average is $113.89. The firm has a market cap of $12.08 billion, a price-to-earnings ratio of 15.66, a PEG ratio of 1.17 and a beta of 1.04.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The company had revenue of $3.07 billion for the quarter, compared to analyst estimates of $3.03 billion. During the same quarter in the prior year, the company earned $1.58 EPS. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. Equities research analysts anticipate that DaVita Inc. will post 9.49 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.